Cabazitaxel is an antineoplastic medicine belonging to the taxane class. It acts on cellular microtubules, disrupting the processes required for cell division and thereby inhibiting the proliferation of susceptible cancer cells.
Recommended for:
Research and clinical evidence:
Because cabazitaxel is a cytotoxic chemotherapy medicine, treatment requires appropriate monitoring of blood counts, liver function, overall condition, and the risk of infectious complications.
Kabanat is indicated in combination with prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.
Cabazitaxel stabilizes microtubules and disrupts their normal dynamics, which are essential for cell division. This results in cell-cycle disruption and death of susceptible tumor cells.
Kabanat is administered intravenously as an infusion by a qualified healthcare professional. The medicine requires specific dilution before administration; the Kabanat preparation procedure includes dilution with the supplied diluent followed by further dilution with either sodium chloride solution or dextrose solution. The manufacturer's documentation specifies administration as a one-hour intravenous infusion.
The dose is individually calculated according to body surface area, the patient's condition, and treatment tolerability. Premedication is recommended to reduce the risk and severity of hypersensitivity reactions. The treatment schedule must be determined by the treating oncologist.
